12 results about "Alcohol addiction" patented technology

The invention discloses a pharmaceutical composition for treating alcohol dependence and a preparation method and application thereof. The pharmaceutical composition is prepared from 100 to 1,000 mg of ascorbic acid, 10 to 40 mg of pyrroloquinoline quinone and pharmaceutically acceptable auxiliary materials. According to the pharmaceutical composition provided by the invention, ascorbic acid and pyrroloquinoline quinone are combined for application, so that the alcohol preference rate of mice is remarkably reduced. In a mouse alcohol dependence model, a mouse taking the pharmaceutical composition shows obvious reduction of alcohol intake, and the alcohol dependence is lower. The pharmaceutical composition provided by the invention has the potential of inhibiting alcohol craving and relieving alcohol addiction behaviors, and can effectively intervene in formation and maintenance of alcohol dependence.

The invention belongs to the technical field of medicines, and discloses a ligustrazine derivative modified based on a monosaccharide structural unit and a preparation method of the ligustrazine derivative. According to the invention, a monosaccharide structural unit is introduced to carry out glycosylation modification on ligustrazine molecules, so that the water solubility, the biological activity and the drug effect durability of ligustrazine are remarkably improved, and the pharmacological characteristics of ligustrazine are optimized; the glycosylation modification not only can improve the solubility and stability of ligustrazine, but also can improve the treatment effect of the ligustrazine in specific diseases (such as alcohol addiction and the like) by increasing the affinity of the ligustrazine to a specific target spot; through the technical scheme, the defects of the existing ligustrazine derivative in the aspects of bioavailability, drug effect persistence and the like can be overcome, and the treatment effect and clinical application value of the ligustrazine derivative are remarkably enhanced; the glycosylated and modified ligustrazine derivative has better targeting property and stability, is suitable for wider clinical treatment requirements, and particularly shows greater application potential in treatment of diseases such as alcohol dependence.

The invention discloses a phosphodiesterase 9A inhibitor for treating alcohol addiction and acute alcoholism, relates to the technical field of medicines, and has the technical key point that the inhibitor is BI-409306. The BI-409306 can influence the drinking behavior of a mouse with alcohol addiction by adjusting synaptic plasticity and intervene the formation of addiction. In addition, the BI can also reduce acute alcohol toxicity injury by recovering the GPX4 level and reducing inflammatory factors. The invention not only lays a research foundation for exploring the effect and mechanism of BI in alcohol addiction in the future, but also provides a new target and thought for clinically treating alcohol addiction.

The present invention provides novel piperidinyl-containing pain-sensitive peptide receptor ligand compounds and pharmaceutical compositions that are useful in the treatment of neurological diseases and disorders wherein such ligands address the negative effects of such disorders. Such neurological diseases and conditions include acute and chronic pain, substance abuse / dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, kidney disease, cardiovascular disease, and Parkinson's disease.

The present invention relates generally to novel multi-agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, for example, diseases and disorders that can be ameliorated by controlling weight loss, plasma glucose and lipid levels, insulin levels and / or insulin secretion, positive myodynamia, reducing catabolism, slowing gastric emptying, and preventing neurodegeneration. Such conditions and disorders include, but are not limited to, control of food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels and / or insulin secretion, positive myodynamia, reduction of catabolism, slowing of gastric emptying, obesity, diabetes and diabetes-related conditions, liver fat-related inflammation and injury. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular diseases, dietetic disorders, and rare obesity genetic diseases such as Prallard-Willi Syndrome, intensive care, insulin resistance and related disorders such as polycystic ovarian Syndrome, obesity, any type of diabetes, including type 1, type 2 and gestational diabetes, as well as diabetes mellitus, such as diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, and diabetes mellitus. And CNS disorders such as prevention of neurodegeneration, depression, alcohol addiction, Alzheimer's disease and Parkinson's disease, and non-alcoholic steatohepatitis (NASH).

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for reducing addiction to alcohol, and for ameliorating, reversing, treating or preventing Alcoholic Liver Disease (ALD), or alcohol-induced brain injury, wherein optionally the alcohol-induced brain injury comprises neuronal death and astrogliosis (reducing alcohol-induced neuronal death and astrogliosis). In alternative embodiments, provided methods for administering to the individual in need thereof a compound or composition capable of inhibiting or decreasing the expression or activity of an IL-17 or IL-17 receptor (IL-17R) or RORγt protein, transcript and / or gene to treat or for use in: reducing addiction to alcohol; or ameliorating, reversing, treating or preventing Alcoholic Liver Disease (ALD) or alcohol-induced brain injury; or, inhibiting ROR γt to effectively block production of IL-17 cytokines and attenuate development of alcohol-induced liver fibrosis and brain damage.

Therapeutic methods and models for use of compounds represented by Structural Formula l-VIII and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, isotopic variations including at least one deuterium atom, and N-oxide thereof for treating alcohol abuse, alcohol addiction or alcohol dependency, alcohol-use disorders and their consequences especially cardiometabolic abnormalities, and fibrotic and inflammatory conditions related to the liver and pancreas in an animal or individual. The therapeutic methods and models relate to use of compounds with favorable in vivo pharmacodynamic profiles towards reducing voluntary alcohol (ethanol) intake and seeking behavior in both male and female subjects.

The invention relates to the use of one or more fructokinase (ketohexokinase) (KHK) inhibitors to both prevent and treat a wide variety of diseases including, but not limited to, alcohol craving, alcohol addiction, alcohol induced liver disease including fatty liver and cirrhosis.

The application discloses a kind of pharmaceutical composition and its purposes in preparation for inhibiting the autonomous intake preference of ethanol. The pharmaceutical composition includes lorcaserin and midazolam. The pharmaceutical composition for inhibiting the autonomous intake preference of ethanol provided by the application can effectively reduce the desire of body to alcohol, is used to treat alcohol dependence, and has significant long-acting characteristics. When the pharmaceutical composition is administered to mice, the absolute amount of active ethanol intake of mice and the relative proportion of ethanol intake compared with the amount of drinking water can be significantly reduced, and the inhibitory effect can last at least 6 days, which is expected to update the treatment plan for alcohol addiction in clinic.

The present disclosure relates to a chemical compound having the general formula (I):wherein R1 is a phenyl group and R2 is a meta-substituted phenyl group; and RTA is a substituted or unsubstituted thiazole ring. The disclosure also relates to said compound according to formula (I), in particular in its diastereomerically pure or enriched form, for use in therapy, in particular for treating and / or preventing age-related cognitive decline. Further, the disclosure relates to said compound according to formula (I) for use in improving cognitive functions, in particular for use in improving the spatial learning capabilities in human individuals. And, disclosure also relates to said compound according to formula (I) for use in the treatment and / or prevention of alcohol addiction, nicotine addiction and / or drug addiction, in particular cocaine and / or metamphetamine addiction.

In some aspects, pharmaceutical compounds are disclosed which may be useful for treating anxiety and / or other disorders. In another aspect, a pharmaceutical composition includes a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle therefor. In yet another aspect, a method of treating anxiety, depression, obsessive-compulsive disorder, tobacco addiction, alcohol addiction, cocaine addiction, headache, cluster headache, or cancer-related or other end-of-life psychological distress involves administering the pharmaceutical composition to an individual in need thereof.

Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and / or opioid antagonists, which demonstrate CNS activity and / or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders.